Drug testing in biological samples vs. maternal surveys for the detection of substance use during whole pregnancy

References

• Keegan J, Parva M, Finnegan M, Gerson A, Belden M. Addiction in pregnancy. J Addict Dis. 2010;29(2):175–91. doi:10.1080/10550881003684723.
   PubMed Web of Science ®Google Scholar
• Shankaran S, Lester BM, Das A, Bauer CR, Bada HS, Lagasse L, Higgins R. Impact of maternal substance use during pregnancy on childhood outcome. Semin Fetal Neonatal Med. 2007;12(2):143–50. doi:10.1016/j.siny.2007.01.002.
   PubMed Web of Science ®Google Scholar
• Behnke M, Smith VC, Committee on Fetus and Newborn. Committee on substance abuse, Committee on fetus and newborn. Prenatal substance abuse: short- and long-term effects on the exposed fetus. Pediatrics. 2013;131(3):e1009–e1024. doi:10.1542/peds.2012-3931.
   PubMed Web of Science ®Google Scholar
• Concheiro-Guisán A, Concheiro M. Bioanalysis during pregnancy: recent advances and novel sampling strategies. Bioanalysis. 2014;6(23):3133–53. doi:10.4155/bio.14.278.
   PubMed Web of Science ®Google Scholar
• Stanwood GD, Levitt P. Drug exposure early in life: functional repercussions of changing neuropharmacology during sensitive period of brain development. Curr Opin Pharmacol. 2004;4(1):65–71. doi:10.1016/j.coph.2003.09.003.
   PubMed Web of Science ®Google Scholar
• European Monitoring Centre for Drugs and Drug Addiction. 2015. Informe annual 2015 [dataset]. Available from http://www.emcdda.europa.eu/system/files/publications/974/TDAT15001ESN.pdf.
   Google Scholar
• Substance Abuse and Mental Health Services Administration. 2014. Results from the 2013 National Survey on Drug Use and Health: Summary of National Findings [dataset]. Available from https://www.samhsa.gov/data/sites/default/files/NSDUHresultsPDFWHTML2013/Web/NSDUHresults2013.pdf.
   Google Scholar
• Substance Abuse and Mental Health Services Administration. 2017. Results from the 2017 National Survey on Drug Use and Health: Summary of National Findings [dataset]. https://www.samhsa.gov/data/sites/default/files/cbhsq-reports/NSDUHDetailedTabs2017/NSDUHDetailedTabs2017.pdf.
   Google Scholar
• Spanish Observatoy for Drugs and Addictions. 2017. Consumo, percepciones y opiniones ante las drogas [dataset]. 2017. Available from http://www.pnsd.mscbs.gob.es/profesionales/sistemasInformacion/sistemaInformacion/pdf/EDADES_2017_Informe.pdf.
   Google Scholar
• Friguls B, Joya X, Garcia-Serra J, Gómez-Culebras M, Pichini S, Martinez S, Vall O, Garcia-Algar O. Assessment of exposure to drugs of abuse during pregnancy by hair analysis in a Mediterranean island. Addiction. 2012;107(8):1471–9. doi:10.1111/j.1360-0443.2012.03828.x.
   PubMed Web of Science ®Google Scholar
• Ostrea EM, Knapp DK, Tannenbaum L, Ostrea AR, Romero A, Salari V, Ager J. Estimates of illicit drug use during pregnancy by maternal interview, hair analysis, and meconium analysis. J Pediatr. 2001;138(3):344–8. doi:10.1067/mpd.2001.111429.
   PubMed Web of Science ®Google Scholar
• Petersen Williams P, Jordaan E, Mathews C, Lombard C, Parry CD. Alcohol and other drug use during pregnancy among women attending midwife obstetric units in the Cape Metropole, South Africa. Adv Prev Med. 2014;2014:871427 doi:10.1155/2014/871427.
   PubMedGoogle Scholar
• Simón L, Pastor-Barriuso R, Boldo E, Fernández-Cuenca R, Ortiz C, Linares C, Medrano MJ, Galán I. Smoke-free legislation in Spain and prematurity. Pediatrics. 2017;139(6):e20162068. doi:10.1542/peds.2016-2068.
   PubMed Web of Science ®Google Scholar
• Ondersma SJ, Chang G, Blake-Lamb T, Gilstad-Hayden K, Orav J, Beatty JR, Goyert GL, Yonkers KA. Accuracy of five self-report screening instruments for substance use in pregnancy. Addiction. 2019;114(9):1683–93. doi:10.1111/add.14651.
   PubMed Web of Science ®Google Scholar
• Gray T, Huestis M. Bioanalytical procedures for monitoring in utero drug exposure. Anal Bioanal Chem. 2007;388(7):1455–65. doi:10.1007/s00216-007-1228-9.
   PubMed Web of Science ®Google Scholar
• Lozano J, García-Algar O, Vall O, de la Torre R, Scaravelli G, Pichini S. Biological matrices for the evaluation of in utero exposure to drugs of abuse. Ther Drug Monit. 2007;29(6):711–34. doi:10.1097/FTD.0b013e31815c14ce.
   PubMed Web of Science ®Google Scholar
• Concheiro M, González-Colmenero E, Lendoiro E, Concheiro-Guisán A, de Castro A, Cruz-Landeira A, López-Rivadulla M. Alternative matrices for cocaine, heroin, and methadone in utero drug exposure detection. Ther Drug Monit. 2013;35(4):502–9. doi:10.1097/FTD.0b013e31828a6148.
   PubMed Web of Science ®Google Scholar
• de Castro A, Díaz A, Piñeiro B, Lendoiro E, Cruz A, López-Rivadulla M, Concheiro M. Simultaneous determination of opiates, methadone, amphetamines, cocaine, and metabolites in human placenta and umbilical cord by LC-MS/MS. Anal Bioanal Chem. 2013;405(12):4295–305. doi:10.1007/s00216-013-6784-6.
   PubMed Web of Science ®Google Scholar
• Lendoiro E, Quintela O, De Castro A, Cruz A, López-Rivadulla M, Concheiro M. Target screening and confirmation of 35 licit and illicit drugs and metabolites in hair by LC-MSMS. Forensic Sci Int. 2012;217(1-3):207–15. doi:10.1016/j.forsciint.2011.11.006.
   PubMed Web of Science ®Google Scholar
• Lendoiro E, González-Colmenero E, Concheiro-Guisán A, De Castro A, Cruz A, López-Rivadulla M, et al. Maternal hair analysis for the detection of illicit drugs, medicines, and alcohol exposure during pregnancy. Ther Drug Monit. 2013;35(3):296–304.
   PubMed Web of Science ®Google Scholar
• Prego-Meleiro P, Lendoiro E, Concheiro M, Cruz A, López-Rivadulla M, De Castro A. Development and validation of a liquid chromatography tandem mass spectrometry method for the determination of cannabinoids and phase I and II metabolites in meconium. J Chromatogr A. 2017;1497:118–26. doi:10.1016/j.chroma.2017.03.066.
   PubMed Web of Science ®Google Scholar
• Joya X, Gomez-Culebras M, Callejón A, Friguls B, Puig C, Ortigosa S, et al. Cocaine use during pregnancy assessed by hair analysis in a Canary Islands cohort. BMC Pegnancy and Childbirth. 2012;12:2–8.
   PubMed Web of Science ®Google Scholar
• Spanish Observatoy for Drugs and Addictions. 2013. Consumo, percepciones y opiniones ante las drogas [dataset]. 2013. Available from http://www.pnsd.msssi.gob.es/profesionales/sistemasInformacion/sistemaInformacion/pdf/2015_Informe_Estadisticas_EDADES.pdf.
   Google Scholar
• Sherwood RA, Keating J, Kavvadia V, Greenough A, Peters TJ. Substance misuse in early pregnancy and relationship to fetal outcome. Eur J Pediatr. 1999;158(6):488–92. doi:10.1007/s004310051126.
   PubMed Web of Science ®Google Scholar
• García-Algar O, Vall Combelles O, Puig Sola C, Mur Sierra A, Scaravelli G, Pacifici R, Monleón Getino T, Pichini S. Exposición prenatal a drogas de abuso a través del análisis de meconio en una población de bajo nivel socioeconómico en Barcelona. An Pediatr. 2009;70(2):151–8. doi:10.1016/j.anpedi.2008.08.008.
   Google Scholar
• Kacinko SL, Jones HE, Johnson RE, Choo RE, Huestis MA. Correlations of maternal buprenorphine dose, buprenorphine, and metabolite concentrations in meconium with neonatal outcomes. Clin Pharmacol Ther. 2008;84(5):604–12. doi:10.1038/clpt.2008.156.
   PubMed Web of Science ®Google Scholar
• Concheiro M, Lendoiro E, de Castro A, Gónzalez-Colmenero E, Concheiro-Guisan A, Peñas-Silva P, Macias-Cortiña M, Cruz-Landeira A, López-Rivadulla M. Bioanalysis for cocaine, opiates, methadone, and amphetamines exposure detection during pregnancy. Drug Test Anal. 2017;9(6):898–904. doi:10.1002/dta.2087.
   PubMed Web of Science ®Google Scholar
• De Castro A, Jones HE, Johnson RE, Gray TR, Shakleya DM, Huestis MA. Methadone, cocaine, opiates, and metabolite disposition in umbilical cord and correlations to maternal methadone dose and neonatal outcomes. Ther Drug Monit. 2011;33(4):443–52. doi:10.1097/FTD.0b013e31822724f0.
   PubMed Web of Science ®Google Scholar
• Wood KE, McMillin GA, Krasowski MD. Risk-Based newborn drug testing in a setting with a low prevalence of maternal drug use. Hosp Pediatr. 2019;9(8):593–600. doi:10.1542/hpeds.2018-0256.
   PubMedGoogle Scholar